Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

v3.20.2
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Current assets    
Cash and cash equivalents $ 78,466 $ 50,412
Marketable securities - available-for-sale debt securities 321,442 39,130
Other current assets and prepaid expenses (including current portion of clinical materials) 26,825 30,947
Total current assets 426,733 120,489
Restricted cash 4,441 4,496
Clinical materials 160 2,503
Operating lease right-of-use assets, net of accumulated amortization 18,775 20,789
Property, plant and equipment, net of accumulated depreciation of $26,100 (2019: $23,649) 26,943 31,068
Intangibles, net of accumulated amortization 1,970 2,198
Total assets 479,022 181,543
Current liabilities    
Accounts payable 4,030 6,357
Operating lease liabilities, current 2,619 2,493
Accrued expenses and other accrued liabilities 24,615 23,363
Deferred revenue, current 3,635 2,128
Total current liabilities 34,899 34,341
Operating lease liabilities, non-current 21,090 22,966
Deferred revenue, non-current 46,212  
Other liabilities, non-current 615 598
Total liabilities 102,816 57,905
Stockholders' equity    
Common stock - Ordinary shares par value ?0.001, 1,038,249,630 authorized and 928,525,410 1,325 943
Additional paid in capital 932,518 585,623
Accumulated other comprehensive loss (8,494) (7,264)
Accumulated deficit (549,143) (455,664)
Total stockholders' equity 376,206 123,638
Total liabilities and stockholders' equity $ 479,022 $ 181,543